Joined: 12/12/2011
Posts: 5174
|
Details are missing, but Anavex's poster presentation at the Alzheimer's Association International Conference is promising:
Study of the Mechanism of Action of Blarcamesine (Anavex 2-73): Whole Blood Transcriptomics Analysis (RNAseq) Identifies Treatment Impact on Compensatory Pathways by Restoring Key Neurodegenerative Pathways Functionality, including Alzheimer's and Parkinson's Disease Pathway
Now if one of those pathways that is restored is the phosphatidylinositol 3-kinase/Akt pathway, then this drug candidate will change the course of the treatment of Alzheimer's and Parkinson's Disease. For it is this pathway that leads to the regeneration of neurons, synapses, and axons in the hippocampus, maintains blood flow in the brain, and limits the death of neurons.
https://79bcf7a1-8b8e-483b-b7cf-f5c5192a6d63.usrfiles.com/ugd/79bcf7_c5813c517d9f4ca5aacbeb719508827a.pdf
|
Joined: 1/1/2018
Posts: 210
|
Hi Lane, are the trials finished? Is Anavex 2-73 availble for dementia sufferers?
|
Joined: 9/5/2022
Posts: 69
|
Hi lane and wolfwoman!
I hope to take part in a trail study for dementia cure.
|
Joined: 12/12/2011
Posts: 5174
|
The Anavex trial finished this summer, but the results are still being analyzed. The company said it would announce results in the Fall. Maybe Late Fall.
|
Joined: 12/12/2011
Posts: 5174
|
Cyclo Therapeutics clinial trial for TrappolCyclo should be recruiting participants soon (further information should be on clinicaltrials.gov before long).
https://cyclotherapeutics.com/cyclo-therapeutics-commences-phase-2b-study-of-trappsol-cyclo-for-the-treatment-of-early-alzheimers-disease/
Unfortunately, this drug candidate has to be given intravenously. The company started the trial based largely on the results from one individual.
After 18 months, the patient showed neurologic and cognitive stability: this is a positive given that persons with Alzheimer's Disease dementia are generally expected to decline during an 18-month timeframe. Speech fluency also improved as documented by the treating physician's report of a decrease in latency to word-finding. In addition, mood and behavioral features of the disease improved, such as less agitation, as noted by the patient, the patient's family and the treating physician.
Trappsol Cyclo reduces cholesterol in the brain and decreases oxidation both of which should help in the treatment of Alzheimer's disease.
|
Joined: 12/12/2011
Posts: 5174
|
Here are the good results from the Anavex trial.
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL
Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results
Plan to Meet with Regulatory Authorities to Determine Next Steps
ANAVEX®2-73 demonstrated visible improvement in patients with Alzheimer’s disease. Patients treated with ANAVEX®2-73 were 84% more likely, to have improved cognition by ADAS-Cog score change of -0.50 points or better from baseline to end of treatment than patients on placebo, Odds Ratio = 1.84 (p = 0.015). On average, patients, who improved cognitively with ANAVEX®2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points. ANAVEX®2-73 treatment was 167% more likely to improve function compared with placebo, at a clinically meaningful improvement of ADCS-ADL score change of +3.5 points or better, Odds Ratio = 2.67 (p=0.0255). This reflects a robust improved and clinically meaningful outcome in cognition and function from baseline.
https://www.anavex.com/post/anavex-2-73-blarcamesine-phase-2b-3-study-met-primary-and-key-secondary-endpoints
|